| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Bacterial cell wall synthesis; penicillin binding protein (PBP)
Cefsulodin sodium inhibits cell wall synthesis by competitively inhibiting penicillin-binding protein (PBP) cross-linking and transpeptidation of peptidoglycan. This results in inhibition of the final transpeptidation step required for bacterial cell wall synthesis. As a third-generation cephalosporin, it has enhanced activity against Pseudomonas aeruginosa. Cefsulodin sodium is also a potent tyrosine phosphatase inhibitor against mPTPB, a virulent phosphatase from Mycobacterium tuberculosis, with an IC50 value of 16 µM. |
|---|---|
| ln Vitro |
At a minimum inhibitory concentration (MIC) of 0.5-64 mg/mL, cefsulodin sodium (0.5-64 mg/mL; 18 hours) has activity against Pseudomonas aeruginosa that is roughly 16–32 times greater than that of carbenicillin[1]. When produced in the presence of penicillin, Pseudomonas aeruginosa-induced beta-lactamases do not hydrolyze cefsulodin sodium (8–16 μg/mL; 4.5 hours) [1].
Cefsulodin sodium is particularly suitable for Pseudomonas aeruginosa infections. It is effective against Pseudomonas aeruginosa and Staphylococcus aureus. However, it has low activity against other bacteria and no significant activity against other Gram-negative bacteria. It has very limited activity against Gram-positive bacteria and anaerobic bacteria. The compound is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests, primarily against Pseudomonas aeruginosa. |
| ln Vivo |
Cefsulodin sodium (1 g/kg/label; i.p.; 9 single doses spaced 12 hours apart over 5 days) demonstrated a threshold for tubular toxicity and increased excretion by renal tubular cells in rats as an indicator of nephrotoxicity. The dose is 250 mg/kg (subcutaneous; 12 days) in 9 single doses [4].
Cefsulodin sodium is particularly suitable for Pseudomonas aeruginosa infections in debilitated patients. It is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests against Pseudomonas aeruginosa. The compound is also used in CIN agar to select for Yersinia microorganisms. Its specific activity against Pseudomonas aeruginosa makes it a valuable tool for studying this pathogen. |
| Enzyme Assay |
Cefsulodin sodium (SCE-129, CGP-7174/E), active in minimum inhibitory concentrations (MICs) of 0.5 to 64 microgram/ml, was about 16- to 32-fold more active than carbenicillin against Psuedomonas aeruginosa. It was also active against P. diminuta, P. maltophilia, P. paucimobilis, and P. pseudoalcaligenes (MICs of 1 to 32 microgram/ml) but not against other species of Pseudomonas or other gram-negative bacteria. Except with highly carbenicillin-resistant isolates, MICs of cefsulodin for P. aeruginosa were little affected by an increase in the inoculum. With a small inoculum, minimum bactericidal concentrations (MBCs) were the same as or twice the MIC, but increasing the inoculum had a greater effect on the MBC than on the MIC. Cefsulodin was not hydrolyzed by the beta-lactamase induced in P. aeruginosa by growth in the presence of benzylpenicillin and was a poor substrate for beta-lactamases from Enterobacter cloacae and Proteus morganii. However, it was hydrolyzed, albeit slowly, by the beta-lactamase produced by most of our highly carbenicillin-resistant isolates of P. aeruginosa and by TEM-type beta-lactamases [2].
Cefsulodin sodium's activity is assessed using standard in vitro microbiological susceptibility testing methods. Minimum inhibitory concentration (MIC) determinations are performed against various bacterial strains, particularly Pseudomonas aeruginosa. The compound's binding affinity to penicillin-binding proteins (PBPs) can be evaluated using competitive binding assays with radiolabeled penicillin. The compound's activity as a tyrosine phosphatase inhibitor can be assessed using enzyme assays. |
| Cell Assay |
mPTPB is a virulent phosphatase from Mycobacterium tuberculosis and a promising therapeutic target for tuberculosis. To facilitate mPTPB-based drug discovery, we identified α-sulfophenylacetic amide (SPAA) from cefsulodin, a third generation β-lactam cephalosporin antibiotic, as a novel pTyr pharmacophore for mPTPB. Structure-guided and fragment-based optimization of SPAA led to the most potent and selective mPTPB inhibitor 9, with a K i of 7.9 nM and more than 10,000-fold preference for mPTPB over a large panel of 25 phosphatases. Compound 9 also exhibited excellent cellular activity and specificity in blocking mPTPB function in macrophage. Given its novel structure, modest molecular mass, and extremely high ligand efficiency (0.46), compound 9 represents an outstanding lead compound for anti-TB drug discovery targeting mPTPB [1].
Cellular assays for cefsulodin sodium are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains, particularly Pseudomonas aeruginosa. Bacterial growth inhibition is assessed by measuring optical density or by counting colony-forming units. The compound's selective activity against Pseudomonas aeruginosa can be evaluated. |
| Animal Protocol |
Animal/Disease Models: Female Wistar rat (200 g) [4]
Doses: 1000 mg/kg/label Route of Administration: intraperitoneal (ip) injection; 5 days; 9 single doses, 12 hrs (hrs (hours)) apart (injection volume: 10mL) Experimental Results: In 5 During days of treatment, tubular cell excretion in 12-hour nocturnal urine increased. In vivo animal model experiments for cefsulodin sodium would involve administration to animal models of Pseudomonas aeruginosa infection to evaluate its efficacy. The compound's specific activity against Pseudomonas aeruginosa makes it suitable for studying infections caused by this pathogen. Such studies are essential for understanding the compound's in vivo behavior and therapeutic potential. |
| ADME/Pharmacokinetics |
Cefsulodin sodium is a third-generation cephalosporin antibiotic. Specific pharmacokinetic data is not extensively detailed in the available literature. As a third-generation cephalosporin, it is expected to have good tissue distribution. The compound is administered parenterally.
|
| Toxicity/Toxicokinetics |
Cefsulodin sodium is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and local reactions at the injection site. The compound is intended for research use only.
|
| References |
[1]. He R, et al. Cefsulodin Inspired Potent and Selective Inhibitors of mPTPB, a Virulent Phosphatase from Mycobacterium tuberculosis. ACS Med Chem Lett. 2015 Nov 3;6(12):1231-5.
[2]. King A, et al. In vitro antibacterial activity and susceptibility of cefsulodin, an antipseudomonal cephalosporin, to beta-lactamases. Antimicrob Agents Chemother. 1980 Feb;17(2):165-9. [3]. Gotoh N, et al. Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. [4]. Sack K, et al. Renal tolerance of imipenem/cilastatin and other beta-lactam antibiotics in rats. Infection. 1985;13 Suppl 1:S156-60. |
| Additional Infomation |
Cefsulodin sodium is an organic molecular entity. Cefsulodin sodium is the sodium salt form of Cefsulodin, a semi-synthetic third-generation cephalosporin antibiotic with narrow-spectrum antibacterial activity. Cefsulodin is effective against Pseudomonas aeruginosa and Staphylococcus aureus, but has low activity against other bacteria. It is a pyridine-substituted semi-synthetic broad-spectrum antibacterial drug, particularly suitable for Pseudomonas aeruginosa infections in debilitated patients. See also: Cefsulodin (note moved to).
Cefsulodine sodium (CAS# 52152-93-9) is a third-generation cephalosporin antibiotic. It is particularly suitable for Pseudomonas aeruginosa infections in debilitated patients. Cefsulodin is effective against Pseudomonas aeruginosa and Staphylococcus aureus, but has low activity against other bacteria. It inhibits cell wall synthesis by competitively inhibiting penicillin-binding protein (PBP) cross-linking. It is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests against Pseudomonas aeruginosa. |
| Molecular Formula |
C22H19N4NAO8S2
|
|---|---|
| Molecular Weight |
554.53
|
| Exact Mass |
554.054
|
| CAS # |
52152-93-9
|
| Related CAS # |
Cefsulodin sodium hydrate;1426397-23-0; 62587-73-9 (free acid); 52152-93-9 (sodium)
|
| PubChem CID |
656644
|
| Appearance |
Off-white to light yellow solid
|
| Melting Point |
175ºC
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
37
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O=C(N[C@H]1[C@@]2([H])SCC(C[N+]3=CC=C(C(N)=O)C=C3)=C(C([O-])=O)N2C1=O)[C@@H](C4=CC=CC=C4)S(=O)([O-])=O.[Na+]
|
| InChi Key |
REACMANCWHKJSM-DWBVFMGKSA-M
|
| InChi Code |
InChI=1S/C22H20N4O8S2.Na/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12;/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34);/q;+1/p-1/t15-,17-,21-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-3-[(4-carbamoylpyridin-1-ium-1-yl)methyl]-8-oxo-7-[[(2R)-2-phenyl-2-sulfonatoacetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
SCE-129 sodium; SCE129 sodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~55 mg/mL (~99.18 mM)
DMSO : ~13.5 mg/mL (~24.34 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.25 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (180.33 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8033 mL | 9.0166 mL | 18.0333 mL | |
| 5 mM | 0.3607 mL | 1.8033 mL | 3.6067 mL | |
| 10 mM | 0.1803 mL | 0.9017 mL | 1.8033 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA